Within this framework, IGFBP-6 is distinctive because it preferentially binds IGF-II, positioning it to modulate a ligand that is frequently upregulated in virally driven and metabolic HCC contexts [109]. The gene discussed is IGF2; the disease is hepatocellular carcinoma.